New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)

New to The Street will expand its Bloomberg Television footprint into Southeast Asia starting Oct. 3, targeting distribution to ~68 million households. The broadcast spotlights Lantern Pharma’s AI-driven oncology drug development, SafeSpace Global’s AI/biometric emergency response safety platform, and FreeCast’s unified streaming platform strategy. While this is primarily promotional/media visibility rather than a financial update, the global audience expansion is modestly supportive for investor awareness of the featured public companies.

Analysis

This is an attention/liquidity event, not a fundamental re-rate. The only durable economic impact is if the coverage expands the companies’ ability to raise capital at better terms or convert exposure into signed commercial deals; otherwise the market usually prices these broadcasts as temporary retail-flow catalysts, not as evidence of revenue acceleration.

Relative winners are the most narrative-sensitive names with the highest elasticity to incremental eyeballs: CAST and LTRN. CAST likely gets the cleaner “distribution platform” story, while LTRN benefits from the AI/biotech label that screens well for momentum capital; SSGC is the most vulnerable to skepticism because OTC promo names tend to see the sharpest post-event mean reversion. Second-order effect: any pop in these names can crowd out capital from other microcap AI/streaming names and briefly widen financing windows for similarly story-driven issuers.

The contrarian miss is that global broadcast reach does not equal qualified demand. Without a near-term filing, partnership announcement, or guidance revision, the conversion rate from media impression to economic value is usually low, and the market tends to fade these setups within days to a few weeks. If the companies can’t show measurable lead generation or signed commercial traction over 1-3 months, the event becomes a dilution-risk signal rather than a growth signal.

Key Decisions for Investors

• Fade event-driven strength in LTRN and SSGC over the next 1-5 trading days if volume spikes 2-3x but no new contract, clinical, or financing update follows; use the post-broadcast high as the risk level.
• If trading CAST, prefer a small tactical long only on confirmation of follow-through volume and a separate fundamental catalyst; otherwise treat the move as a short-covering/liquidity pop with limited 1-3 month upside.
• Highest-risk short remains SSGC: initiate only after the first squeeze fades and keep stops tight above the event-day high, because OTC names can remain disconnected from fundamentals longer than expected.
• Set a 2-6 week watch item on all three names for disclosed customer wins, capital raises, or partnership announcements; absent that, the thesis shifts from “visibility” to “dilution-assisted marketing,” which is bearish.